Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Mar 16:1:13.
doi: 10.21037/tgh.2016.03.13. eCollection 2016.

Sorafenib in adjuvant setting: call for precise and personalized therapy

Wei Zhang  1
Affiliations
Comment

Sorafenib in adjuvant setting: call for precise and personalized therapy

Wei Zhang. Transl Gastroenterol Hepatol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author has no conflicts of interest to declare.

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015;16:1344-54. 10.1016/S1470-2045(15)00198-9 - DOI - PubMed
    1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90. 10.1056/NEJMoa0708857 - DOI - PubMed
    1. Lencioni R, Llovet JM, Han G, et al. Sorafenib or Placebo plus TACE with Doxorubicin-Eluting Beads for Intermediate-Stage HCC: Phase II, Randomized, Double-Blind SPACE Trial. J Hepatol 2016. Doi: 10.1016/j.jhep.2016.01.012 - DOI - PubMed
    1. Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011;47:2117-27. 10.1016/j.ejca.2011.05.007 - DOI - PubMed
    1. Mountzios G, Pentheroudakis G, Carmeliet P. Bevacizumab and micrometastases: revisiting the preclinical and clinical rollercoaster. Pharmacol Ther 2014;141:117-24. 10.1016/j.pharmthera.2013.09.003 - DOI - PubMed

LinkOut - more resources